In the first week of the Year of the Horse, 857 companies disclosed performance briefings, with 4 companies experiencing net profit growth of over 10 times.

In the first week of the Year of the Horse, A-share listed companies’ earnings saw a wave of concentrated disclosures. According to Tonghuashun iFind statistics, as of February 28, during the first week of the Year of the Horse, 857 A-share listed companies had already released their 2025 performance express reports, and 470 companies’ net profit attributable to the parent achieved year-over-year growth. Among them, the electronic, mechanical equipment, and biopharmaceutical industries ranked in the top three by share, with 97, 77, and 69 companies respectively, showing strong underlying support for their performance fundamentals.

In terms of revenue growth, the “dark horse” on cost growth is the pharma company Haichuang Pharma on the STAR Market. Its performance express report shows that in 2025, Haichuang Pharma achieved operating revenue of 21M yuan, up dramatically 5536.26% year over year. The growth mainly came from the drug sales revenue generated after its first Class 1 new drug, Deuternzarulamine Soft Capsules (project number: HC-1119), was approved for marketing and sales in May 2025. However, in 2025, the company’s net profit attributable to the parent still recorded a loss of 137M yuan, though it narrowed the loss by 31.48% compared with the same period last year.

Haichuang Pharma said that although the product has already been launched, it was not included in the National Reimbursement Drug List until December 2025. Due to factors such as price difference adjustments and changes in its marketing model affecting the timing of revenue recognition, the company’s revenue for the period was impacted. In addition, the company is still in the early stage of commercialization, with substantial R&D and market investment, and has not yet achieved profitability. (21st Century Business Herald)